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Background: Passively acquired maternal derived immunity (MDI) is a double-edged sword. Maternal derived antibody-
mediated immunity (AMI) and cell-mediated immunity (CMI) are critical immediate defenses for the neonate;
however, MDI may interfere with the induction of active immunity in the neonate, i.e. passive interference. The
effect of antigen-specific MDI on vaccine-induced AMI and CMI responses to Mycoplasma hyopneumoniae
(M. hyopneumoniae) was assessed in neonatal piglets. To determine whether CMI and AMI responses could be
induced in piglets with MDI, piglets with high and low levels of maternal M. hyopneumoniae-specific immunity were
vaccinated against M. hyopneumoniae at 7 d of age. Piglet M. hyopneumoniae-specific antibody, lymphoproliferation,
and delayed type hypersensitivity (DTH) responses were measured 7 d and 14 d post vaccination.
Results: Piglets with M. hyopneumoniae-specific MDI failed to show vaccine-induced AMI responses; there was no
rise in M. hyopneumoniae antibody levels following vaccination of piglets in the presence of M. hyopneumoniae-specific
MDI. However, piglets with M. hyopneumoniae-specific MDI had primary (antigen-specific lymphoproliferation) and
secondary (DTH) M. hyopneumoniae-specific CMI responses following vaccination.
Conclusions: In this study neonatal M. hyopneumoniae-specific CMI was not subject to passive interference by MDI.
Further, it appears that both maternal derived and endogenous CMI contribute to M. hyopneumoniae-specific CMI
responses in piglets vaccinated in the face of MDI.
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Infectious disease is a major contributor to morbidity and
mortality among infants, children, and other young ani-
mals. Ideally, strategies should be practiced at an early age
to confer protection from infectious disease-related mor-
bidity and mortality experienced later in life. Vaccination is
a commonly used disease intervention strategy; however,
there are many issues that complicate vaccinating neonates
including vaccine safety and vaccine efficacy. Vaccination
regimens may be unsuccessful in stimulating protective
immunity in neonates due to both ontogenic immune im-
maturity and passively acquired maternal derived immun-
ity (MDI) interfering with active immune development.* Correspondence: molit001@umn.edu
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reproduction in any medium, provided the orMDI is a critical contributor to the neonatal immune re-
sponse. MDI is passively transferred to neonates across
the placenta and via colostrum and milk in humans and
mice [1-3] but only via colostrum and milk in pigs [4],
horses [5], and cattle [6]. MDI is directly responsible for
preventing or reducing the impact of infectious diseases in
the neonate. In piglets MDI has been shown to be at least
partially protective against many agents including Escheri-
chia coli [7,8], Mycoplasma hyopneumoniae (M. hyopneu-
moniae) [9], Transmissible Gastroenteritis virus (TGE)
[10], and Porcine Circovirus type 2 (PCV2) [11]. However,
MDI may interfere with adaptive immune responses fol-
lowing vaccination, i.e. passive interference. For example,
young pigs vaccinated in the face of antigen-specific MDI
have suppressed antibody responses to M. hyopneumoniae
[12], Bordetella bronchiseptica [13], Pseudorabies [14], Swine
Influenza Virus (SIV) [15,16], and Classical Swine Fever
(CSF) [17]. Further, while both cell-mediated immune (CMI)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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transferred to neonates via colostrum, the amount of
transferred maternal antibodies can often be correlated
to the level of inhibition of neonatal AMI responses.
Effects of maternal derived CMI on neonatal immune
response development are less well understood. Whether
neonatal CMI responses following vaccination or chal-
lenge are inhibited in the face of MDI is unclear.
Maternal CMI that is transferred to neonates across
the placenta or in colostrum clearly participates in the
neonatal CMI response. Transfer of functional tuberculin-
specific immune cells, as evidenced by delayed-type hyper-
sensitivity (DTH), has been demonstrated in infants from
vaccinated mothers [18]. Transfer of CMI sensitivity to
Trichinella spiralis and Coccidioides immitis antigens, as
evidenced by antigen-specific proliferation and nematode
load, and DTH, respectively, has been demonstrated in
neonatal mice born to vaccinated dams [19,20]. Further,
lymphocytes isolated from calves having received colos-
tral cells from bovine viral diarrheal virus (BVDV) vacci-
nated mothers demonstrated greater CMI responsiveness
to BVDV compared to lymphocytes isolated from calves
receiving acellular colostrum [21]. We have shown that
maternal colostral cells from M. hyopneumoniae vacci-
nated dams are transferred to piglets and participate in
the in vivo neonatal CMI response to M. hyopneumoniae
upon antigen challenge [22]. Still, it is unclear whether

















Figure 1 Sow response to Mycoplasma hyopneumoniae vaccination. M.
in sow blood and colostrum. Black bars represent vaccinated sows; gray bars
n = 10/group. Error bars are SEM; different subscripts represent significanc
measured in serum and colostrum of vaccinated and nonvaccinated sow
CMI was measured in sow colostrum via lymphoproliferation. Antigen specific
only) lymphoproliferation from M. hyopneumoniae specific lymphoproliferatioor otherwise affects active CMI response development in
the piglet. In other words, whether piglets vaccinated in
the face of MDI develop antigen-specific CMI responses
remains to be elucidated.
CMI is critical in the immune response to M. hyopneu-
moniae [23-26] and maternal M. hyopneumoniae-specific
cells participate in the immune response following M.
hyopneumoniae antigen challenge in piglets [22]. This
study was conducted to test the hypothesis that piglets
respond to M. hyopneumoniae vaccination with CMI
but not AMI responses when vaccinated in the face of
M. hyopneumoniae-specific MDI in a field setting. Piglets
with M. hyopneumoniae-specific MDI failed to show
vaccine induced AMI responses. In contrast, piglets with
M. hyopneumoniae-specific MDI and vaccinated against
M. hyopneumoniae developed primary and secondary M.
hyopneumoniae-specific CMI responses.
Results
Sow response to vaccination
Prior to experimental vaccination, sows had M. hyopneu-
moniae-specific antibodies (Figure 1A) as expected due to
prior on-farm vaccination.M. hyopneumoniae experimental
vaccination of sows increased M. hyopneumoniae-specific
AMI responses in blood and colostrum (Figure 1A) and M.
hyopneumoniae-specific lymphoproliferative responses in
colostrum (Figure 1B). Sows vaccinated in this study had

































































hyopneumoniae specific AMI (panel A) and CMI (panel B) were measured
represent nonvaccinated sows; white bars represent sows pre-vaccination;
e at p < 0.05. A. M. hyopneumoniae specific antibody S:P ratios were
s using the Idexx HerdCheckTM ELISA. B. M. hyopneumoniae specific
lymphoproliferation was determined by subtracting unstimulated (media
n.
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vaccination (p = 0.0001) and compared to sows not vacci-
nated as part of this study (p = 0.002; Figure 1A). Similarly,
experimentally vaccinated sows had significantly greater
M. hyopneumoniae-specific antibody S:P ratios in colos-
trum compared to nonvaccinated sows (Figure 1A). Colostral
mononuclear cells (CMC) from experimentally vaccinated
sows demonstrated significantly greater M. hyopneumoniae-
specific proliferation compared to CMC from nonvacci-
nated sows (p = 0.04; Figure 1B).
Passive transfer of M. hyopneumoniae-specific immunity
to piglets
Newborn piglets are naïve to M. hyopneumoniae (the
swine placenta prohibits transfer of immune components
in utero), and there is no evidence of transplacental infec-
tion with M. hyopneumoniae. Prior to colostrum ingestion
piglets did not demonstrate M. hyopneumoniae-specific
immunity, either AMI (Figure 2A) or CMI (Figure 2B).
Following colostrum ingestion, piglets from vaccinated
sows had significantly greater M. hyopneumoniae antibody
S:P ratios compared to piglets from nonvaccinated sows
(p = 0.0001; Figure 2A). Blood mononuclear cells (BMC)
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Figure 2 M. hyopneumoniae specific immunity is transferred to piglet
measured in piglet blood before (n = 7/group) and 24 hrs after (n = 10/gro
sows; gray bars represent piglets from nonvaccinated sows. Error bars are S
measured in serum of piglets pre-suckling and 24 hrs after suckling using t
measured in piglet blood via lymphoproliferation. Antigen-specific lympho
lymphoproliferation (media only) from percent M. hyopneumoniae-specificsuckling proliferated significantly more in response to
stimulation with M. hyopneumoniae antigen compared to
BMC isolated from piglets of nonvaccinated sows (p = 0.04;
Figure 2B). There was no difference in M. hyopneumoniae-
specific antibody S:P ratios or lymphoproliferation relative
to piglet treatment group prior to piglet vaccination (data
not shown).
Piglet response to vaccination
M. hyopneumoniae vaccine was administered when pig-
lets were 7 d of age. Piglets were vaccinated at 7 d of
age in an attempt to stimulate endogenous immunity in
the presence of transferred antigen specific MDI. M.
hyopneumoniae-specific antibody levels did not differ
among piglets from nonvaccinated sows relative to piglet
vaccination status 7 days post vaccination (dpv; Figure 3A)
or 14 dpv (Figure 3B). Two piglets that were considered
M. hyopneumoniae-antibody negative based on S:P ratio
did respond to vaccination with AMI responses by 14 dpv,
though the magnitude of the response was not great
enough to result in a difference between piglet groups.
While the M. hyopneumoniae-specific antibody S:P ratio
among piglets from nonvaccinated sows appeared lower at
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Time at piglet blood sampling
s. M. hyopneumoniae specific AMI (panel A) and CMI (panel B) were
up) colostrum ingestion. Black bars represent piglets from vaccinated
EM; *: p < 0.05. A. M. hyopneumoniae-specific antibody S:P ratios were
he Idexx HerdCheckTM ELISA. B. M. hyopneumoniae specific CMI was
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Figure 3 M. hyopneumoniae antibodies in piglet blood. M. hyopneumoniae specific antibody S:P ratios were measured in piglet blood 7 days
post vaccination (dpv) (panel A) and 14 dpv (panel B) using the Idexx HerdCheck™ ELISA. Piglet treatment groups are as follows: Ns Np: nonvaccinated
sow, nonvaccinated piglet; Ns Vp: nonvaccinated sow, vaccinated piglet; Vs Vp: vaccinated sow, vaccinated piglet; Vs Np: vaccinated sow, nonvaccinated
piglet; n = 10/group. Error bars are SEM; different subscripts represent significance at p < 0.05.
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dpv to 14 dpv. M. hyopneumoniae-specific antibody S:P
ratios among piglets from vaccinated sows were not differ-
ent 7 dpv relative to piglet vaccination status (Figure 3A).
There was no change in mean M. hyopneumoniae-specific
antibody S:P ratio among nonvaccinated piglets from
vaccinated sows (Vs Np) from 7 dpv to 14 dpv; however,
vaccinated piglets from vaccinated sows (Vs Vp) had lower
M. hyopneumoniae-specific antibody S:P ratios at 14 dpv
compared to 7 dpv (p = 0.05). Vs Np piglets had greater M.
hyopneumoniae antibody S:P ratios compared to Vs Vp
piglets 14 dpv (Figure 3B).
To assess piglet M. hyopneumoniae-specific CMI ex vivo,
M. hyopneumoniae-specific proliferation was assessed.
Proliferative responses to concanavalin A (conA) were de-
tected from BMC across piglets at both 7 dpv and 14 dpv
(data not shown). Vaccination in the presence of MDI
(Vs Vp piglets) resulted in earlier M. hyopneumoniae-
specific proliferative responses (7 dpv) compared to all
other groups of piglets (Figure 4A). Interestingly, BMC
isolated from vaccinated piglets proliferated significantly
more in response to stimulation with M. hyopneumoniae
compared to BMC isolated from nonvaccinated piglets
regardless of sow vaccination status 14 dpv (p < 0.01;
Figure 4B). There was no difference in proliferation by
BMC isolated from Ns Vp compared to Vs Vp piglets at 14
dpv. BMC isolated 14 dpv from Vs Vp piglets proliferatedmore in response to stimulation with M. hyopneumoniae
than BMC isolated from the same group of piglets at 7
dpv. Similarly, M. hyopneumoniae-specific proliferative re-
sponses from Ns Vp piglets at 14 dpv were significantly
greater than those from the same group of piglets at 7 dpv.
To assess piglet M. hyopneumoniae-specific CMI in vivo,
DTH testing was performed. In control DTH tests, piglets
across treatment groups responded to phytohemagglutinin
(PHA) and none responded to saline at both injection
times (7 dpv and 14 dpv; data not shown). M. hyopneumo-
niae-specific DTH lesions were detected in some piglets
across all treatment groups at both time points (Figure 5).
Vs Vp piglets had significantly larger M. hyopneumoniae-
specific DTH lesions (mean orthogonal diameter) com-
pared to all other treatment groups at 7 dpv (p < 0.01;
Figure 5A). M. hyopneumoniae-specific DTH lesions
among nonvaccinated piglets did not differ in orthog-
onal diameter 14 dpv (Figure 5B). The mean orthogonal
diameter of M. hyopneumoniae-specific lesions of non-
vaccinated piglets was smaller than that of Ns Vp piglets
(p = 0.05) and Vs Vp piglets (p = 0.01) (Figure 5B) 14 dpv.
In contrast to proliferative responses, M. hyopneumoniae-
specific DTH lesions of Vs Vp piglets were significantly
larger than that of Ns Vp piglets (p = 0.01) 14 dpv. The
mean orthogonal diameter of M. hyopneumoniae-specific
DTH lesions was significantly larger at 14 dpv compared
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Piglet Treatment
Figure 4 M. hyopneumoniae-specific proliferation. M. hyopneumoniae specific proliferation by piglet blood mononuclear cells (BMC) was
measured 7 days post vaccination (dpv) (panel A) and 14 dpv (panel B). Antigen-specific lymphoproliferation was determined by subtracting the
percent unstimulated lymphoproliferation (media only) from the percent M. hyopneumoniae specific lymphoproliferation. Piglet treatment groups
are as follows: Ns Np: nonvaccinated sow, nonvaccinated piglet; Ns Vp: nonvaccinated sow, vaccinated piglet; Vs Vp: vaccinated sow, vaccinated
piglet; Vs Np: vaccinated sow, nonvaccinated piglet; n = 10/group. Error bars are SEM; different subscripts represent significance at p < 0.05.
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Maternal derived antibodies and lymphocytes acquired
across the placenta or postnatally in colostrum or milk
are critical participants in the neonatal immune re-
sponse. Neonatal vaccination has been practiced across a
variety of antigens in an effort to confer protection from
specific pathogens during the period in which the neo-
natal immune system matures and maternal antibodies
wane. However, MDI may interfere with immune prim-
ing and the generation of memory responses following
neonatal vaccination.
This study was conducted to determine whether neo-
natal piglets respond with AMI and/or CMI responses
to M. hyopneumoniae vaccination when vaccinated in
the face of maternal M. hyopneumoniae-specific immun-
ity. To determine whether CMI and AMI responses
could be induced in piglets with MDI, piglets from M.
hyopneumoniae vaccinated and nonvaccinated dams
were vaccinated against M. hyopneumoniae at 7 d of age.
Piglet M. hyopneumoniae-specific antibody, lymphopro-
liferative, and DTH responses were measured 7 dpv and
14 dpv. Vaccination of piglets from vaccinated sows did
not induce AMI responses in those piglets; there was no
rise in M. hyopneumoniae S:P ratios following piglet
vaccination. In contrast, evidence from both antigen-
specific proliferation and DTH testing demonstrates that
M. hyopneumoniae-specific CMI priming and anamnesticresponses are induced following vaccination of piglets with
M. hyopneumoniae-specific MDI. Taken together, neonatal
piglet M. hyopneumoniae-specific CMI responses induced
by vaccination are not (at least wholly) inhibited by passive
interference with M. hyopneumoniae-specific MDI.
In the present study, there is no evidence that piglets
vaccinated in the face of MDI developed active M.
hyopneumoniae-specific AMI responses within 14 dpv.
These results are in agreement with Hodgins et al. [12]
who showed no rise in serum M. hyopneumoniae anti-
body titer 9 weeks post vaccination in piglets vacci-
nated at 14 d of age in the presence of high levels of
antigen-specific MDI [12]. The lack of rise in M. hyop-
neumoniae antibody S:P ratios in piglets vaccinated in
the face of MDI is most likely due to passive interfer-
ence; however, this cannot be concluded with certainty
in the current study as a group of vaccinated piglets
lacking M. hyopneumoniae-specific maternal immunity
was not included. However, piglets with low levels of
maternal M. hyopneumoniae-specific AMI at the time
of vaccination did produce M. hyopneumoniae-specific
antibodies following vaccination, indicating that vaccin-
ation can induce AMI responses in 7 d old pigs dependent
upon the level of maternal antigen-specific AMI in agree-
ment with [12]. It is possible that more piglets responded
to M. hyopneumoniae vaccination with IgM responses;
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Figure 5 M. hyopneumoniae-specific DTH responses. M. hyopneumoniae specific DTH responses were measured 7 days post vaccination (dpv)
(panel A) and 14 dpv (panel B) in piglets. Each diamond represents an individual animal; horizontal bars represent sample means. Piglets were
DTH tested at one time point only; n = 10/group. Piglet treatment groups are as follows: Ns Np: nonvaccinated sow, nonvaccinated piglet; Ns Vp:
nonvaccinated sow, vaccinated piglet; Vs Vp: vaccinated sow, vaccinated piglet; Vs Np: vaccinated sow, nonvaccinated piglet. Different subscripts
represent significance at p < 0.05.
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samples tested. While including a group of SPF piglets
may have resulted in more clear interference results,
SPF piglets are not representative of most commercial
pigs. Further, as M. hyopneumoniae vaccination is one
of the most commonly used vaccines across swine
farms [27], the data in this report represent field condi-
tions. It is unclear why M. hyopneumoniae S:P ratios
were greater in Vs Np piglets compared to Vs Vp piglets
at 14 dpv; this difference may be attributable to inter-
animal variation.
There is a plethora of data demonstrating passive
interference by maternal immunity with neonatal AMI
responses following vaccination; however, reports asses-
sing CMI responses following neonatal vaccination in
the face of MDI are limited. Not only is there a paucity
of information regarding the neonatal CMI response to
vaccination in the face of MDI, the information that
does exist is largely restricted to in vitro studies. For ex-
ample, antigen specific proliferative responses and cyto-
kine production have been demonstrated in infants
vaccinated against measles virus [28], and neonatal mice
vaccinated against measles virus [29,30] and lymphocytic
choriomeningitis virus [31] following vaccination in the
face of antigen-specific MDI. Notably, humans and mice
are exposed to MDI during gestation, and the detectionof antigen-specific reactivity in the neonate may be a re-
sult of antigen priming while in utero [32,33]. The lack
of exposure to MDI prenatally make pigs, cattle, and
horses excellent models to study the role of colostral im-
munity in the neonate, yet few reports have investigated
CMI following neonatal vaccination of these species.
The current study shows that piglets with MDI respond
to M. hyopneumoniae vaccination with antigen specific
CMI responses, and unlike previous studies, we show
evidence of CMI stimulation in vivo. DTH testing is a
valuable measure of CMI since the DTH test is an
in vivo test and DTH responses are by definition anam-
nestic responses.
In agreement with the present study, Bouma et al. [34]
showed that 3-week-old piglets challenged with pseudo-
rabies virus developed virus-specific proliferative responses
regardless of maternal pseudorabies status. Further, piglets
with pseudorabies-specific MDI and vaccinated against
pseudorabies had lower pseudorabies virus antibody titers
than their counterparts without pseudorabies-specific MDI
[34]. Similarly, calves vaccinated against BVDV in the face
of MDI developed CMI responses and did not show evi-
dence of anamnestic AMI responses upon re-exposure to
the antigen [35]. Interestingly, calves vaccinated against
BVDV are protected from disease even in the absence of a
specific AMI response [35,36]. Therefore, just because
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sponses following vaccination in the face of MDI does
not signify that there is an inhibition of the immune re-
sponse. Rather, vaccination may induce CMI responses
that are protective. Collectively these studies show that
neonates are capable of generating CMI responses in
the face of MDI and that passively transferred MDI
may not interfere with neonatal CMI.
Neonatal vaccination in the face of passive immunity
does not always result in CMI responses. The capacity for
neonates with MDI to generate CMI responses following
vaccination may depend on their age and immune matur-
ation at vaccination. Further, the concentration of mater-
nal AMI at the time of vaccination may play a role in the
neonatal immune response since the level of interference
may be dependent on the level of maternal AMI in the
neonate [37]. For example, piglets vaccinated against SIV
[16] or CSF [38] do not experience CMI stimulation when
vaccinated in the face of high levels of antigen-specific
maternal AMI but do show evidence of CMI stimulation
following vaccination when levels of maternal antibodies
are low. Further, the capacity for neonates to generate spe-
cific CMI responses in the face of MDI may be reliant on
the administration method of the vaccine. For example,
piglets with MDI specific for and vaccinated against
pseudorabies shed less virus when vaccine was adminis-
tered intranasally compared to intramuscularly [39].
Vaccine type or immunogenicity may also influence the
neonate’s response to vaccination. DNA vaccines are an
especially alluring neonatal vaccination paradigm since
they replicate in vivo but do not pose a risk of infection.
Some DNA vaccines induce immune responses in neo-
nates when administered in the face of MDI [29,40,41]
while others do not [29,42,43]. Further, adjuvants that
enhance CMI or antigen presentation (such as CpG
motifs) may help the neonatal immune system over-
come the opposing effects of maternal AMI [44].
Differences in neonatal responses to vaccination may also
be due to the presence of functional maternal lymphoid
cells at the time of vaccination. Various studies have shown
that transferred maternal cells augment the neonatal re-
sponse to nonspecific [45,46] and specific [18-20,22] anti-
gens. In the current study piglets vaccinated against M.
hyopneumoniae in the face of M. hyopneumoniae-specific
MDI (Vs Vp piglets) exhibited greater M. hyopneumoniae
specific CMI responses 7 dpv compared to all other groups.
Therefore, CMI priming and anamnestic responses at 7
dpv depended upon piglet vaccination and transferred
antigen-specific MDI. Capozzo et al. [29] showed that neo-
natal mice vaccinated against measles virus in the face of
measles virus-specific MDI exhibited greater measles-
specific CMI responsiveness (IFN-γ production and lym-
phoproliferation) compared to neonatal mice vaccinated
against measles but without virus-specific MDI. Takentogether, these studies suggest that MDI plays a role in the
vaccine-induced CMI response detected in neonates.
Capozzo et al. [29] suggested that the CMI responses
observed in mice vaccinated against measles virus in the
face of measles virus-specific MDI was due to neonatal
T cells that were stimulated by endogenous dendritic
cells that had engulfed maternal antibodies bound to
measles antigens [29]. In support of the idea proposed
by Capozzo et al. that neonatal cells are responding to
vaccine antigen, in this study, since DTH lesions and
proliferative responses were greater in Ns Vp piglets
compared to Ns Np piglets 14 dpv, it is reasonable to
conclude that piglet derived T cells are contributing to
the neonatal response to M. hyopneumoniae antigen. In
addition to neonatal cells responding to vaccination, we
suggest that the CMI responses observed at 7 dpv are
also due to the functional activity (proliferation or secre-
tion of soluble immune mediators, e.g. cytokines) of
transferred antigen-specific maternal lymphocytes that
are restimulated via neonatal vaccination. We have previ-
ously shown that maternal lymphocytes primed during
vaccination are transferred to and are functional in piglets
[22]. Here we show that transferred maternal cells may be
stimulated via piglet vaccination—at 7 dpv lymphoprolif-
erative and DTH responses by Vs Vp piglets were greater
than those of Ns Vp piglets. Further research is required to
determine if these responses are protective.
Evidence suggests that maternal microchimerism (retained
maternal cells or DNA) persists into adulthood [47];
however, it is unclear for how long maternal cells are func-
tional in the offspring. In terms of strategizing vaccination
regimens to take advantage of both endogenous and pas-
sive immunity, the persistence of functional activity of ma-
ternal CMI in the recipient warrants elucidation. Whether
the persistence of function rather than merely presence
(anergy) of maternal CMI in the recipient requires antigen
stimulation is to be determined.Conclusion
In the present study, we showed that maternal M.
hyopneumoniae-specific AMI and CMI is transferred
to and detectable in piglets. Further, transferred ma-
ternal M. hyopneumoniae-specific CMI is functional
and works in concert with vaccine stimulated en-
dogenous M. hyopneumoniae-specific CMI to respond to
M. hyopneumoniae in the piglet. We also demonstrated
that vaccination was sufficient to prime a 7 day-old piglet’s
immune system. Piglets developed M. hyopneumoniae-
specific CMI responses when vaccinated in the face of
MDI. In conclusion, vaccination of neonatal pigs against
M. hyopneumoniae in the face of antigen-specific MDI re-
sults in CMI priming and anamnestic CMI responses fol-
lowing subsequent exposure to M. hyopneumoniae antigen.
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Animals
This study was approved by the University of Minnesota’s
Institutional Animal Care and Use Committee and all
animals were cared for and housed under the University
of Minnesota’s Institutional Animal Care and Use Com-
mittee guidelines. At all times during the study, animals
were housed at a commercial facility (Prairie Land Pork,
Nicollet, MN) known to be porcine reproductive and
respiratory syndrome virus negative. According to the
facility’s protocol, replacement gilts were vaccinated
against M. hyopneumoniae (Myco Silencer, Intervet,
Whitehouse Station, NJ, USA) at days 17 and 45 of gilt
acclimatization by farm staff; the total acclimatization
period was 110 days. Randomly selected piglets from
the farm were tested for M. hyopneumoniae by PCR fol-
lowing nasal swabbing prior to starting the present study
[48].M. hyopneumoniae-specific PCR testing was performed
using a previously described protocol [49]. All swabs were
negative for M. hyopneumoniae DNA, indicating that M.
hyopneumoniae was not circulating on the farm.
Animals were chosen to participate in this study based
on breeding date and on gilt and first parity sow status.
An equal number of gilts and first parity sows (from
here known as sows) were randomly stratified into one
of two groups: boosted or primed, based on previous
on-farm vaccination. Boosted animals were vaccinated as
part of this study and are referred to as “vaccinated”
while primed animals were not vaccinated as part of this
study and are referred to as “nonvaccinated.” Experimen-
tal vaccination was against M. hyopneumoniae (Respisure-
One®, Pfizer Animal Health, Kalamazoo, MI, USA), an
adjuvanted bacterin. Respisure-One®, labeled for single
dose administration in healthy swine one day of age or
older, was given (2 ml intramuscular) at 5 and 3 weeks
prior to the anticipated farrowing date.
Farrowings were monitored and piglets were ear-
tagged at birth. To ensure piglets received both maternal
CMI and AMI, no cross-fostering was practiced among
study animals [50]. Eighty piglets (n = 3 per sow) were
chosen based on sow vaccination status. Twenty piglets
from vaccinated sows and 20 piglets from nonvaccinated
sows were selected randomly and immunized with the
same vaccine as given to the sows. Piglet vaccine was ad-
ministered at 7 d according to manufacturer guidelines
and resulted in four treatment groups of 20 piglets each as
follows: (1) sow vaccination, piglet vaccination (Vs Vp); (2)
sow vaccination, piglet nonvaccination (Vs Np); (3) sow
nonvaccination, piglet vaccination (Ns Vp); and (4) sow
nonvaccination, piglet nonvaccination (Ns Np).
Sampling
Blood collection of sows occurred at 5 weeks prepartum
and 3 weeks postpartum. Blood was collected from thejugular vein into EDTA Vacutainer® tubes (BD, Franklin
Lakes, NJ, USA). Colostrum was collected from all sows
within 2 hrs of farrowing. Teats were scrubbed with alco-
hol wipes (70%; Medline, Mundelein, IL, USA) and gloves
were worn to minimize sample contamination. Colostrum
(25 ml) was collected manually from all functional teats.
Blood was collected from piglets before colostrum inges-
tion, 24 hr after colostrum ingestion, and at 14, and 21 days
of age. Blood was collected via jugular venipuncture into
sterile EDTA Vacutainer® tubes. Blood sampling times are
expressed in terms of days post vaccination (dpv).
Laboratory methods
Mononuclear cell isolation and stimulation
Mononuclear cells were isolated from sow and piglet
blood via Ficoll density centrifugation as described [51]
with modifications. Piglet blood was diluted 1:2 in sterile
PBS prior to layering on lymphocyte separation media to
improve cell recovery yield. Mononuclear cells were iso-
lated from colostrum as described [52]. Cells were micro-
scopically enumerated and viability was assessed via Trypan
Blue exclusion. Viability of blood mononuclear cells (BMC)
was at least 95% and viability of colostral mononuclear cells
(CMC) was at least 90%.
A dye-dilution method was used in order to evaluate
the lymphoproliferative response to M. hyopneumoniae.
Cells were stained with the membrane stain carboxyfluo-
rescein diacetate succinimidyl ester (CFSE; 5 μM; ICT,
Bloomington, MN, USA) and washed with RPMI supple-
mented with 10% FBS, 100 U penicillin G per ml, and
100 μg of streptomycin per ml to stop the reaction. Cells
were resuspended in RPMI and plated in duplicate at
5×105 cells/well in 200 μl in round bottom 96-well
plates. CMC and BMC were stimulated with 10 μg/ml
M. hyopneumoniae antigen as described [26]. The M.
hyopneumoniae antigen was prepared as described [22];
M. hyopneumoniae at passage 15 was harvested by con-
tinuous flow centrifugation at 70,000 x g and resuspended
in Tris-sodium chloride buffer. M. hyopneumoniae was
inactivated by one freeze-thaw cycle and then by sonic dis-
ruption. Nonstimulated and ConA (5 μg/ml; Sigma-Aldrich,
St. Louis, MO, USA) stimulated cultures served as negative
and positive controls, respectively. Experimental, negative,
and positive controls were analyzed for each animal.
Following 5 d incubation, cells were transferred to
sterile Facs tubes and washed. Proliferation was ana-
lyzed by flow cytometry using a Facs Caliber flow cyt-
ometer (Becton Dickinson Immunocytometry System,
San Jose, CA, USA). Non-stained, non-stimulated cells
and stained, non-stimulated cells were used to establish
a baseline for the proliferation assay. Event acquisition
was set for 10,000 events in a region encompassing the
CFSE-positive quadrant. Results were analyzed by BD
Cellquest™ Pro software (BD Biosciences, San Jose, CA,
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proliferation - nonstimulated proliferation.
DTH testing
DTH testing was used as an in vivo measure of the CMI
response. The DTH assay for M. hyopneumoniae was
performed as originally applied [23] with modifications.
The M. hyopneumoniae antigen used in the DTH assay
was the same antigen as used in the in vitro proliferation
assay. M. hyopneumoniae antigen (300 μg/ml in 0.1 ml
physiological saline) was injected intradermally in 10
piglets per group at 14 d of age and a second set of 10
piglets per group at 21 d of age. PHA (20 μg/ml in
0.1 ml physiological saline; Sigma, St. Louis, MO, USA)
and physiological saline (0.1 ml) were used as positive
and negative controls, respectively. Injections were per-
formed in the inguinal region. Injection sites were clearly
marked with livestock paint. The DTH injection sites
were assessed immediately and 36 h post injection. DTH
lesion diameters were measured with digital calipers;
DTH data are shown as mean orthogonal diameter of in-
duration. Piglets were subject to DTH testing only once
to avoid the possibility of the DTH antigens influencing
subsequent DTH test results.
Antibody measurement
M. hyopneumoniae-specific antibodies were measured in
all blood and colostrum samples employing Idexx ELISA
kits (IDEXX Laboratories, Westbrook, Maine, USA) as
described [53]. The Idexx M. hyopneumoniae ELISA kit
is isotype non-specific. Positive and negative M. hyop-
neumoniae serological status was determined based on
optical density (OD) of the sample to positive ratio (S:P);
S:P = (sample OD - negative control OD)/(positive con-
trol OD - negative control OD). All samples were run in
duplicate and sample means were used to determine the
final S:P ratio. S:P ratios ≥0.4 were classified as positive;
S:P ratios <0.4 were classified as negative.
Data analysis and statistics
Normality of data was evaluated prior to statistical analysis
and approximated to be normal. The difference in M.
hyopneumoniae-specific antibody S:P ratio in sow sera be-
fore and after vaccination, the difference between M.
hyopneumoniae-specific antibody S:P ratios in sera and
colostrum of vaccinated or nonvaccinated sows, and the
difference between M. hyopneumoniae-specific prolifera-
tion by CMC isolated from vaccinated or nonvaccinated
sows was analyzed by the student t-test. The effect of pig-
let vaccination on M. hyopneumoniae-specific AMI and
CMI responses (piglet M. hyopneumoniae-specific anti-
body S:P ratios, M. hyopneumoniae-specific proliferation,
and M. hyopneumoniae-specific DTH lesion size) wasanalyzed via two-way ANOVA with piglet vaccination and
sow vaccination being the two factors. Comparisons found
to be significant by ANOVA (p < 0.05) were analyzed by
Tukey’s HSD method. Student t-test was used to analyze
the difference in mean M. hyopneumoniae-specific DTH
lesion orthogonal diameter and the difference in M. hyop-
neumoniae-specific antibody S:P ratios between 7 dpv and
14 dpv among piglets of the same group. Statistical ana-
lysis was performed using GraphPad Prism 5 (Graph Pad
Software, Inc, CA, USA).
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